Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

ClinicalTrials.gov ID: NCT01330966

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01330966. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.

Study identification

NCT ID: NCT01330966
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Emerald Clinical Inc.; Industry
Enrollment: 47 participants

Conditions and interventions

Conditions

Interventions

pazopanib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2011 (Type not available)
Primary completion: Feb 2018 (Actual)
Completion: Feb 2018 (Actual)
Last update posted: Mar 10, 2023

2011 – 2018

United States locations

U.S. sites: 6
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	—
Edward Cancer Center	Naperville	Illinois	60540	—
University of Iowa	Iowa City	Iowa	52242	—
Mayo Clinic	Rochester	Minnesota	55905	—
Pennsylvania Oncology Hematology Associates	Philadelphia	Pennsylvania	19106	—
MD Anderson	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01330966, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 10, 2023 · Synced Nov 15, 2026